Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.

IF 2.4 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of Bone and Mineral Metabolism Pub Date : 2024-03-01 Epub Date: 2024-03-17 DOI:10.1007/s00774-024-01497-4

Hisashi Matsushima, Tetsuya Taguchi, Sho Kodama, Naoki Okubo, Kengo Saito, Katarzyna Jabłońska, Seiji Fukumoto, Toshio Matsumoto

{"title":"Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.","authors":"Hisashi Matsushima, Tetsuya Taguchi, Sho Kodama, Naoki Okubo, Kengo Saito, Katarzyna Jabłońska, Seiji Fukumoto, Toshio Matsumoto","doi":"10.1007/s00774-024-01497-4","DOIUrl":null,"url":null,"abstract":"Introduction: Androgen deprivation therapy (ADT) is widely used for the treatment of prostate cancer. ADT is associated with reduced bone density leading to an increased risk of osteoporotic fracture. The objective of this retrospective cohort study was to quantify fracture risk in men treated with ADT for prostate cancer in real-world practice in Japan.Materials and methods: Data were extracted from the Japanese Medical Data Vision (MDV) database. Men initiating ADT for treatment of prostate cancer between April 2010 and March 2021 were identified and matched to a cohort of prostate cancer patients not taking ADT using a propensity score. Fracture rates were estimated by a cumulative incidence function and compared between cohorts using a Cox cause-specific hazard model. Information was extracted on demographics, comorbidities and bone densitometry.Results: 30,561 men with PC starting ADT were matched to 30,561 men with prostate cancer not treated with ADT. Following ADT initiation, <5% of men underwent bone densitometry. Prescription of ADT was associated with an increased fracture risk compared to not taking ADT (adjusted hazard ratio: 1.63 [95% CI 1.52-1.75]).Conclusion: ADT is associated with a 1.6-fold increase in the risk of osteoporotic fracture in men with prostate cancer. Densitometry in this population is infrequent and monitoring urgently needs to be improved in order to implement effective fracture prevention.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"223-232"},"PeriodicalIF":2.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982088/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Mineral Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00774-024-01497-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Androgen deprivation therapy (ADT) is widely used for the treatment of prostate cancer. ADT is associated with reduced bone density leading to an increased risk of osteoporotic fracture. The objective of this retrospective cohort study was to quantify fracture risk in men treated with ADT for prostate cancer in real-world practice in Japan.

Materials and methods: Data were extracted from the Japanese Medical Data Vision (MDV) database. Men initiating ADT for treatment of prostate cancer between April 2010 and March 2021 were identified and matched to a cohort of prostate cancer patients not taking ADT using a propensity score. Fracture rates were estimated by a cumulative incidence function and compared between cohorts using a Cox cause-specific hazard model. Information was extracted on demographics, comorbidities and bone densitometry.

Results: 30,561 men with PC starting ADT were matched to 30,561 men with prostate cancer not treated with ADT. Following ADT initiation, <5% of men underwent bone densitometry. Prescription of ADT was associated with an increased fracture risk compared to not taking ADT (adjusted hazard ratio: 1.63 [95% CI 1.52-1.75]).

Conclusion: ADT is associated with a 1.6-fold increase in the risk of osteoporotic fracture in men with prostate cancer. Densitometry in this population is infrequent and monitoring urgently needs to be improved in order to implement effective fracture prevention.

查看原文本刊更多论文

与雄激素剥夺疗法相关的前列腺癌患者骨折风险：日本保险理赔数据库研究。

简介：雄激素剥夺疗法（ADT）被广泛用于治疗前列腺癌：雄激素剥夺疗法（ADT）被广泛用于治疗前列腺癌。ADT 会导致骨密度降低，从而增加骨质疏松性骨折的风险。这项回顾性队列研究的目的是量化日本现实世界中使用 ADT 治疗前列腺癌的男性的骨折风险：数据提取自日本医疗数据视野（MDV）数据库。在 2010 年 4 月至 2021 年 3 月期间开始使用 ADT 治疗前列腺癌的男性被识别出来，并通过倾向评分与未使用 ADT 的前列腺癌患者队列进行匹配。通过累积发病率函数估算骨折发生率，并使用 Cox 特定病因危险模型比较不同队列之间的骨折发生率。研究人员还提取了有关人口统计学、合并症和骨密度测量的信息：结果：30,561 名患有前列腺癌并开始 ADT 治疗的男性与 30,561 名未接受 ADT 治疗的男性进行了配对。结果：30,561 名 PC 患者开始接受 ADT 治疗，30,561 名前列腺癌患者未接受 ADT 治疗：ADT与前列腺癌男性骨质疏松性骨折风险增加1.6倍有关。该人群的骨密度测量并不频繁，因此急需改善监测，以有效预防骨折。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Bone and Mineral Metabolism 医学-内分泌学与代谢

CiteScore

6.30

自引率

3.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal of Bone and Mineral Metabolism (JBMM) provides an international forum for researchers and clinicians to present and discuss topics relevant to bone, teeth, and mineral metabolism, as well as joint and musculoskeletal disorders. The journal welcomes the submission of manuscripts from any country. Membership in the society is not a prerequisite for submission. Acceptance is based on the originality, significance, and validity of the material presented. The journal is aimed at researchers and clinicians dedicated to improvements in research, development, and patient-care in the fields of bone and mineral metabolism.